Screener
Theravance Biopharma TBPH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $288,101 | $167,806 |
| Short-term marketable securities | 106,565 | 147,551 |
| Receivables from collaborative arrangements | 15,584 | 45,539 |
| Receivables from milestones and royalty assets | — | 50,000 |
| Other prepaid and current assets | 7,384 | 7,564 |
| Total current assets | 417,634 | 418,460 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's cash & equivalents?
- Theravance Biopharma (TBPH) reported cash & equivalents of $288.1M in Q1 2026.
- How has Theravance Biopharma's cash & equivalents changed year-over-year?
- Theravance Biopharma's cash & equivalents increased by 160.5% year-over-year, from $110.61M to $288.1M.
- What is the long-term trend for Theravance Biopharma's cash & equivalents?
- Over 5 years (2020 to 2025), Theravance Biopharma's cash & equivalents has grown at a 15.5% compound annual growth rate (CAGR), from $81.47M to $167.81M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Theravance Biopharma's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude